bioAffinity Technologies, Inc. Common Stock BIAF · NASDAQ
$3.17 -11.20% (-$0.40)
Summary
36 / 100 · Bulios Score
What speaks for it
- Revenue grew by 987% a year over the last 3 years.
- It holds more cash than debt: $2.43M against $1.44M.
What to watch
- The company made a loss over the last 12 months.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 987% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $15.2M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Health Care, Patient Service 100%
- Other Revenues 0.1%
By region
The company reports no revenue by region.
Health Care, Patient Service brings in 100% of revenue.
Segments in detail